Mr. Robert Friedland Joins Board of Directors

News

Dragon Pharmaceuticals Inc. is very pleased to announce the appointment of international financier Robert Friedland to the Board of Directors, effective immediately.

Friedland is chairman and president of Ivanhoe Capital Corporation, a Singapore-based venture capital company with worldwide interests in resource and high-tech companies.

Companies developed or financed by Friedland and Ivanhoe Capital include Ivanhoe Energy, Ivanhoe Mines, Diamond Fields Resources, Golden Star Resources, Fairbanks Gold, Cyber City Holdings (a Chinese company establishing high-tech science parks) and SINA.com (a global Internet media company).

Friedland is chairman and acting president of Ivanhoe Mines and deputy chairman of Ivanhoe Energy, which is active in China in partnership with China National Petroleum Corporation through its subsidiary Sunwing Energy Ltd. Friedland was named Developer of the Year in 1996 by the Canadian Prospectors and Developers Association of Canada for his work in establishing and financing international mining and exploration companies, including Diamond Fields, owner and developer of the Voisey’s Bay nickel deposit, which was sold to INCO Limited for CDN $4.3 billion.

The Company is very pleased with the appointment of Friedland. Dragon has entered into an exciting time of growth and development. Friedland brings a wealth of experience to the Company and will undoubtedly be an invaluable addition to the Board of Directors. The entire Board of Directors looks forward to working with Friedland during the years ahead.

The Company also wishes to announce that Jackson Cheng has resigned as a director of the Company to allow for the appointment of Friedland. The Board wishes to thank Cheng for his contributions to the management of the Company.

Dragon Pharmaceuticals, the largest EPO producer in China, is currently a leading biotech company focusing on the research, development, production and marketing of biodrugs throughout China.

Legal Dragon Pharma Steroids

Generic drug giant Dragon Pharma is offering: buy Parabolan.

No Tags

3418 total views, 1 today

Popular
Comments
Tags

Dragon Ships EPO Internationally

Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced that it has filled orders for recombinant erythropoietin (EPO) from Egypt, India and Peru where, in addition to China, the Company’s EPO is approved for use in the treatment of anemia related to chronic renal failure. All dollar amounts are stated in US dollars. “Penetrating new markets […]
Dragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results

Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights Generated revenues of $7.36 million, representing significant growth from $3.07 million in 2001. Enhancement of gross margin in 2002 to 86.7% from 81% in 2001. Reported a first ever operating profit of […]
Dragon Announces Participation at Biopartnering Europe 2001

Dragon Pharmaceuticals Inc. (OTC BB – DRUG.OB) is pleased to announce that it has been invited to present at the BioPartnering Europe 2001 conference to be held at the Queen Elizabeth II Conference Centre in London, England from October 14th to 16th, 2001. BioPartnering Europe is the premier European venue for showcasing innovative biopharmaceutical and […]
Dragon Launches EPO Into the Brazilian Market

Dragon Pharmaceuticals Inc. (OTC BB: DRUG; TSX: DDD) today announced that it has shipped an order of recombinant erythropoietin (“EPO? to Itaca Laboratorios Ltda., (“Itaca” of Brazil. Itaca, a distribution partner of the company, has won a 3.1 million Brazilian Real tender for Dragon’s EPO in the Brazilian state of Minas, Gerais, which converts to […]
Dragon Signs Licensing Agreement for Korea

Dragon Pharmaceuticals Inc. (OTCBB – DRUG.OB) today announced that it has entered into a marketing and licensing agreement with Boryung Biopharma Company, Ltd. of Seoul, Korea for the distribution of recombinant Erythropoietin (EPO) in North and South Korea. According to the agreement, Boryung Biopharma will also be responsible for obtaining marketing for EPO from the […]